Understanding APC

Denosumab Demonstrates An Increased Time to First Skeletal Event in Men with Metastatic Prostate Cancer vs Zometa

In men with bone metastasis from castration-resistant prostate cancer (CRPC), a monthly subcutaneous injection with denosumab, 120 mg, is superior to Zometa, a multinational group of researchers reported at the American Society of Clinical Oncology annual meeting. The current standard of care is for men with bone metastasis from castration-resistant prostate cancer (CRPC) is to [...]

By |2017-10-19T10:53:43-04:00August 11th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, Metastases, Uncategorized, Understanding APC|0 Comments
Read More

Acupuncture for Hot Flashes in Men with Prostate Cancer

In men with prostate cancer hot flashes are one of the most commonly reported adverse effects of hormonal therapy (ADT). Researchers at the Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon wanted to confirm the many reports that acupuncture can moderate hot flashes. […]

By |2010-08-10T07:05:05-04:00August 10th, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, How We Live, Uncategorized, Understanding APC|0 Comments
Read More

A Systematic Review – Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy?

One of the largest and most controversial issues for the treatment of advanced prostate cancer is the value of androgen-deprivation therapy (ADT). Most doctors use ADT as their pivotal initial treatment in the management of locally advanced and metastatic prostate cancer (PCa). But, the grand question is does it extend survival? […]

By |2010-08-07T12:55:26-04:00August 7th, 2010|Advanced Prostate Cancer, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments
Read More

A Take Away Point from the Last American Urological Association (AUA) Meeting

The prognosis of patients with advanced prostate cancer who have lymph node metastasis depends on the number of positive lymph nodes removed and Gleason score of the primary tumor. Bilateral pelvic lymph node dissection should be performed in intermediate- and high-risk patients to identify those with minimal nodal burden who may benefit the most from [...]

By |2010-08-06T11:55:52-04:00August 6th, 2010|Advanced Prostate Cancer, General Information, Metastases, Prostate Ponderings, Uncategorized, Understanding APC|0 Comments
Read More

Carboplatin plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer

UroToday.com published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). […]

By |2017-10-19T10:53:44-04:00August 5th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments
Read More

Should Degarelix Be Accompanied By An Antiandrogen?

On the Advanced Prostate Cancer Listserv there was a question raised about the need to use an antiandrogen (bicalutamide/Casodex, flutamide/Eulexin, or nilutamide/Nilandron) along with degarelix, the recently approved LHRH antagonist (a drug that halts the production of testicular androgens). Doctors who are knowledgeable about the use of LHRH antagonists (Zoladex, Lupron, Eligard, Viadur and Firmagon [...]

By |2017-10-19T10:53:44-04:00August 3rd, 2010|Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|11 Comments
Read More

Degarelix Shows Promise as Second-Line Hormonal Therapy for Men With Prostate Cancer

When Degarelix (FIRMAGON) which is a gonadotrophin-releasing hormone (GnRH) receptor blocker was first approved by the Food and Drug Administration (FDA) I contacted Ferring Pharmaceuticals and spoke with their medical director. I asked if Degarelix could be used as a second line hormone therapy drug after the traditional first line GnRH agonist drugs (Lupron etc.) [...]

By |2017-10-19T10:53:45-04:00August 2nd, 2010|Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, On The Horizon, Research, Uncategorized, Understanding APC|2 Comments
Read More

Should I go on to Hormone Therapy – What about the Risk of Thromboembolic Diseases

(Results from the population-based PCBaSe Sweden) Hormone therapy (ADT) is designed to prevent the manufacturing of testosterone however, testosterone is a very important preventive hormone, especially in the area of heart health. ADT also causes a number of metabolic side-effects including increased body weight, insulin resistance, dyslipidemia, and hyperglycemia. So, how is the risk of [...]

By |2017-10-19T10:53:45-04:00August 1st, 2010|Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments
Read More
Go to Top